Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background and Aims: Take‐home naloxone can prevent death from heroin/opioid overdose, but pre‐provision is difficult because naloxone is usually given by injection. Non‐injectable alternatives, including naloxone nasal sprays, are currently being developed. To be effective, the intranasal (i.n.) spray dose must be adequate but not excessive, and early absorption must be comparable to intramuscular (i.m.) injection. We report on the pharmacokinetics (PK) of a specially produced concentrated novel nasal spray. The specific aims were to: (1) estimate PK profiles of i.n. naloxone, (2) compare early systemic exposure with i.n. versus i.m. naloxone and (3) estimate i.n. bioavailability. Design: Open‐label, randomized, five‐way cross‐over PK study. Setting: Clinical trials facility (Croydon, UK). Participants: Thirty‐eight healthy volunteers (age 20–54 years; 11 female). Intervention and comparator: Three doses of i.n. (1 mg/0.1 ml, 2 mg/0.1 ml, 4 mg/0.2 ml) versus 0.4 mg i.m. (reference) and 0.4 mg intravenous (i.v.) naloxone. Measurements: Regular blood samples were taken, with high‐frequency sampling during the first 15 minutes to capture early systemic exposure. PK parameters were determined from plasma naloxone concentrations. Exploratory analyses involved simulation of repeat administration. Findings: Mean peak concentration (C max) values for 1 mg (1.51 ng/ml), 2 mg (2.87 ng/ml) and 4 mg (6.02 ng/ml) i.n. exceeded 0.4 mg i.m. (1.27 ng/ml) naloxone. All three i.n. doses rapidly achieved plasma levels > 50% of peak concentrations (T50%) by 10 minutes, peaking at 15–30 minutes (T max). For comparison, the i.m. reference reached T max at 10 minutes. Mean bioavailability was 47–51% for i.n. relative to i.m. naloxone. Simulation of repeat dosing (2 × 2 mg i.n. versus 5 × 0.4 mg i.m. doses) at 3‐minute intervals showed that comparable plasma naloxone concentrations would be anticipated. Conclusions: Concentrated 2 mg intranasal naloxone is well‐absorbed and provides early exposure comparable to 0.4 mg intramuscular naloxone, following the 0.4 mg intramuscular curve closely in the first 10 minutes post‐dosing and maintaining blood levels above twice the intramuscular reference for the next 2 hours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saved by the nose: Bystander-administered intranasal naloxone hydrochloride for opioid overdose
Doe-Simkins, M., Walley, A. Y., Epstein, A., & Moyer, P. (2009) · American Journal of Public Health · doi:10.2105/ajph.2008.146647 · Cited by 250 · cited 1×
“During the 2000s, various groups began introducing improvised nasal spray kits, consisting of a syringe pre-filled with the most concentrated injectable naloxone solution available (1 mg/ml) and a Mucosal Atomisation Device [4].”
Method
Cited by
Medication Treatment of Opioid Use Disorder
Bell, J., & Strang, J. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.06.020 · Cited by 328
Self-citationAlgera, M. H., Kamp, J., van der Schrier, R., van Velzen, M., Niesters, M., Aarts, L., Dahan, A., & Olofsen, E. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.12.023 · Cited by 123
Treatment of opioid overdose: current approaches and recent advances
Britch, S. C., & Walsh, S. L. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06125-5 · Cited by 96
Clinical Pharmacokinetics and Pharmacodynamics of Naloxone
Saari, T. I., Strang, J., & Dale, O. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01355-6 · Cited by 77
Self-citation
Metadata
- Authors
- McDonald, R., Lorch, U., Woodward, J., Bosse, B., Dooner, H., Mundin, G., Smith, K., & Strang, J.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2017-11-16
- Volume
- 113
- Issue
- 3
- Pages
- 484-493
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2768998640
- Cited by
- 97
- References
- 1
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.